Pharvaris to Present Clinical Data in Phoenix This November
The pharmaceutical company will showcase new research at the 2026 ACAAI Annual Scientific Meeting in Arizona.
Updated on Oct. 29, 2026 in Allergies
Live Poll
Do you believe upcoming clinical trial results will provide better treatment options for your health needs?
Pharvaris will present data from November 12-16, 2026, at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix. The program will include one oral presentation and five poster presentations featuring the company's research.
Why it matters
These presentations provide the medical community and investors with insights into the clinical development and real-world performance of new allergy treatments. The data releases are intended to share findings directly from active studies conducted by the pharmaceutical firm.
Pharvaris is slated to deliver one late-breaking oral presentation and five poster presentations during the multi-day event. These findings include data from the Phase 3 CHAPTER-3 study of oral deucrictibant extended-release tablets.
The players
Pharvaris
A biopharmaceutical company headquartered in Zug, Switzerland, that focuses on developing therapies for hereditary angioedema.
American College of Allergy, Asthma & Immunology
A professional medical association that hosts the Annual Scientific Meeting to share research with healthcare practitioners.
The details
The presentations will detail findings on hereditary angioedema economic burdens and safety evaluations from the CHAPTER-1 trial. All slide decks and posters will be uploaded to the company investor portal during the conference.
Timeline
The ACAAI 2026 Annual Scientific Meeting runs from November 12-16, 2026.
A poster presentation on deucrictibant immediate-release capsules occurs on November 13, 2026.
Presentations regarding hereditary angioedema and CHAPTER-3 trials are scheduled for November 14, 2026.
Safety evaluation and CHAPTER-1 extension posters will be presented on November 15, 2026.
The Big Picture
This event marks a critical milestone for the CHAPTER-3 clinical trial by transitioning the study from private research to public scientific discourse. The findings contribute to the broader trajectory of therapeutic development for hereditary angioedema treatments.
These presentations provide the latest scientific evidence regarding new medication options that could eventually impact treatment plans for allergy patients. Healthcare providers and patients can look for updated information on efficacy and safety through official disclosure channels.
The takeaway
Patients and clinicians monitoring the development of new allergy treatments should review the upcoming data disclosures for insights into patient safety. These findings will help define the role of new therapies like deucrictibant in clinical practice moving forward.
Further reading
For more information on the latest research and industry developments, visit the Allergies section.
More information
To track the latest updates from the conference, visit the Pharvaris events and presentations portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe upcoming clinical trial results will provide better treatment options for your health needs?
